{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T17:10:40Z","timestamp":1778519440073,"version":"3.51.4"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,9]],"date-time":"2021-12-09T00:00:00Z","timestamp":1639008000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004359","name":"Swedish Research Council","doi-asserted-by":"publisher","award":["2020-01302"],"award-info":[{"award-number":["2020-01302"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Swedish Research Council","doi-asserted-by":"publisher","award":["2018-02547"],"award-info":[{"award-number":["2018-02547"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013368","name":"German National Academy of Sciences Leopoldina","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013368","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002794","name":"Cancerfonden","doi-asserted-by":"publisher","award":["19 0267"],"award-info":[{"award-number":["19 0267"]}],"id":[{"id":"10.13039\/501100002794","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002794","name":"Cancerfonden","doi-asserted-by":"publisher","award":["CAN 19 0266"],"award-info":[{"award-number":["CAN 19 0266"]}],"id":[{"id":"10.13039\/501100002794","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001381","name":"National Research Foundation","doi-asserted-by":"publisher","award":["NRF-NRFF2017-02"],"award-info":[{"award-number":["NRF-NRFF2017-02"]}],"id":[{"id":"10.13039\/501100001381","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001348","name":"Agency for Science, Technology and Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001348","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004348","name":"Stockholms L\u00e4ns Landsting","doi-asserted-by":"publisher","award":["CAN 2020-0714"],"award-info":[{"award-number":["CAN 2020-0714"]}],"id":[{"id":"10.13039\/501100004348","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004348","name":"Stockholms L\u00e4ns Landsting","doi-asserted-by":"publisher","award":["20200102"],"award-info":[{"award-number":["20200102"]}],"id":[{"id":"10.13039\/501100004348","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.ejca.2021.12.003","type":"journal-article","created":{"date-parts":[[2022,1,10]],"date-time":"2022-01-10T12:17:08Z","timestamp":1641817028000},"page":"194-205","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Interval breast cancer is associated with interferon immune response"],"prefix":"10.1016","volume":"162","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3201-6416","authenticated-orcid":false,"given":"Emilio","family":"Ugalde-Morales","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Felix","family":"Grassmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keith","family":"Humphreys","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8587-7511","authenticated-orcid":false,"given":"Jingmei","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8135-4270","authenticated-orcid":false,"given":"Mikael","family":"Eriksson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2343-9772","authenticated-orcid":false,"given":"Nicholas P.","family":"Tobin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linda S.","family":"Lindstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johan","family":"Vallon-Christersson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c5ke","family":"Borg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Per","family":"Hall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kamila","family":"Czene","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2021.12.003_bib1","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1093\/jnci\/92.9.743","article-title":"Biologic characteristics of interval and screen-detected breast cancers","volume":"92","author":"Gilliland","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ejca.2021.12.003_bib2","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1001\/jamaoncol.2018.0352","article-title":"Breast cancer with a poor prognosis diagnosed after screening mammography with negative results","volume":"4","author":"McCarthy","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ejca.2021.12.003_bib3","doi-asserted-by":"crossref","first-page":"27","DOI":"10.3816\/CBC.2011.n.005","article-title":"Comparison of clinical-pathologic characteristics and outcomes of true interval and screen-detected invasive breast cancer among participants of a Canadian breast screening program: a nested case-control study","volume":"11","author":"Rayson","year":"2011","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.ejca.2021.12.003_bib4","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1093\/jnci\/djr138","article-title":"Tumor characteristics associated with mammographic detection of breast cancer in the Ontario breast screening program","volume":"103","author":"Kirsh","year":"2011","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ejca.2021.12.003_bib5","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1093\/jnci\/91.23.2020","article-title":"Breast tumor characteristics as predictors of mammographic detection: comparison of interval- and screen-detected cancers","volume":"91","author":"Porter","year":"1999","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ejca.2021.12.003_bib6","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1097\/CEJ.0b013e328354d324","article-title":"Aggressiveness features and outcomes of true interval cancers: comparison between screen-detected and symptom-detected cancers","volume":"22","author":"Domingo","year":"2013","journal-title":"Eur J Cancer Prev"},{"key":"10.1016\/j.ejca.2021.12.003_bib7","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1093\/jnci\/djr043","article-title":"Independent prognostic value of screen detection in invasive breast cancer","volume":"103","author":"Mook","year":"2011","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ejca.2021.12.003_bib8","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1200\/JCO.2014.58.9986","article-title":"Risk factors and tumor characteristics of interval cancers by mammographic density","volume":"33","author":"Holm","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2021.12.003_bib9","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1158\/1078-0432.CCR-16-0967","article-title":"Molecular differences between screen-detected and interval breast cancers are largely explained by PAM50 subtypes","volume":"23","author":"Li","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2021.12.003_bib10","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1200\/JCO.2008.18.1370","article-title":"Supervised risk predictor of breast cancer based on intrinsic subtypes","volume":"27","author":"Parker","year":"2009","journal-title":"J Clin Oncol"},{"issue":"Suppl 2","key":"10.1016\/j.ejca.2021.12.003_bib11","doi-asserted-by":"crossref","first-page":"S26","DOI":"10.1016\/j.breast.2015.07.008","article-title":"Clinical implications of the intrinsic molecular subtypes of breast cancer","volume":"24","author":"Prat","year":"2015","journal-title":"Breast"},{"key":"10.1016\/j.ejca.2021.12.003_bib12","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1158\/1940-6207.CAPR-17-0368","article-title":"PAM50 and risk of recurrence scores for interval breast cancers","volume":"11","author":"Puvanesarajah","year":"2018","journal-title":"Cancer Prev Res (Phila)."},{"key":"10.1016\/j.ejca.2021.12.003_bib13","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1093\/annonc\/mdu565","article-title":"Breast cancer genetic risk profile is differentially associated with interval and screen-detected breast cancers","volume":"26","author":"Li","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2021.12.003_bib14","doi-asserted-by":"crossref","DOI":"10.1093\/ije\/dyw357","article-title":"Cohort profile: the Karolinska mammography Project for risk prediction of breast cancer (KARMA)","volume":"46","author":"Gabrielson","year":"2017","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.ejca.2021.12.003_bib15","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1158\/0008-5472.CAN-14-3706","article-title":"Endothelial ALK1 is a therapeutic target to block metastatic dissemination of breast cancer","volume":"75","author":"Cunha","year":"2015","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejca.2021.12.003_bib16","doi-asserted-by":"crossref","DOI":"10.1158\/0008-5472.SABCS13-P6-06-17","article-title":"Abstract P6-06-17: gene signature model predicts metastatic onset better than standard clinical markers Nested case-control design uniquely enables enrichment for biologically relevant features","volume":"73","author":"Lindstr\u00f6m","year":"2013","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejca.2021.12.003_bib17","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/nature11412","article-title":"Comprehensive molecular portraits of human breast tumours","volume":"490","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.ejca.2021.12.003_bib18","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1111\/joim.12303","article-title":"Review of 103 Swedish Healthcare quality registries","volume":"277","author":"Emilsson","year":"2015","journal-title":"J Intern Med"},{"key":"10.1016\/j.ejca.2021.12.003_bib19","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1159\/000321255","article-title":"Breast cancer screening program in Stockholm County, Sweden - aspects of organization and quality assurance","volume":"5","author":"Lind","year":"2010","journal-title":"Breast Care (Basel)"},{"key":"10.1016\/j.ejca.2021.12.003_bib20","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/s10549-018-4690-5","article-title":"A comprehensive tool for measuring mammographic density changes over time","volume":"169","author":"Eriksson","year":"2018","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ejca.2021.12.003_bib21","doi-asserted-by":"crossref","first-page":"4648","DOI":"10.1038\/s41467-019-12652-1","article-title":"Interval breast cancer is associated with other types of tumors","volume":"10","author":"Grassmann","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.ejca.2021.12.003_bib22","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1093\/jnci\/dju357","article-title":"Absolute assignment of breast cancer intrinsic molecular subtype","volume":"107","author":"Paquet","year":"2015","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ejca.2021.12.003_bib23","first-page":"147","article-title":"TNBCtype: a subtyping tool for triple-negative breast cancer","volume":"11","author":"Chen","year":"2012","journal-title":"Cancer Inf"},{"key":"10.1016\/j.ejca.2021.12.003_bib24","doi-asserted-by":"crossref","first-page":"e0157368","DOI":"10.1371\/journal.pone.0157368","article-title":"Refinement of triple-negative breast cancer molecular subtypes: implications for neoadjuvant chemotherapy selection","volume":"11","author":"Lehmann","year":"2016","journal-title":"PLos One"},{"key":"10.1016\/j.ejca.2021.12.003_bib25","doi-asserted-by":"crossref","first-page":"2612","DOI":"10.1038\/ncomms3612","article-title":"Inferring tumour purity and stromal and immune cell admixture from expression data","volume":"4","author":"Yoshihara","year":"2013","journal-title":"Nat Commun"},{"key":"10.1016\/j.ejca.2021.12.003_bib26","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s10549-016-4041-3","article-title":"Co-expression modules identified from published immune signatures reveal five distinct immune subtypes in breast cancer","volume":"161","author":"Amara","year":"2017","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ejca.2021.12.003_bib27","doi-asserted-by":"crossref","first-page":"4288","DOI":"10.1093\/nar\/gks042","article-title":"Differential expression analysis of multifactor RNA-Seq experiments with respect to biological variation","volume":"40","author":"McCarthy","year":"2012","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.ejca.2021.12.003_bib28","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1093\/bioinformatics\/btp616","article-title":"edgeR: a Bioconductor package for differential expression analysis of digital gene expression data","volume":"26","author":"Robinson","year":"2010","journal-title":"Bioinformatics"},{"key":"10.1016\/j.ejca.2021.12.003_bib29","doi-asserted-by":"crossref","first-page":"4378","DOI":"10.1093\/nar\/gkt111","article-title":"Enriching the gene set analysis of genome-wide data by incorporating directionality of gene expression and combining statistical hypotheses and methods","volume":"41","author":"Varemo","year":"2013","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.ejca.2021.12.003_bib30","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.cels.2015.12.004","article-title":"The Molecular Signatures Database (MSigDB) hallmark gene set collection","volume":"1","author":"Liberzon","year":"2015","journal-title":"Cell Syst"},{"key":"10.1016\/j.ejca.2021.12.003_bib31","doi-asserted-by":"crossref","first-page":"D607","DOI":"10.1093\/nar\/gky1131","article-title":"STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets","volume":"47","author":"Szklarczyk","year":"2019","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.ejca.2021.12.003_bib32","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1093\/bioinformatics\/btr665","article-title":"SomaticSniper: identification of somatic point mutations in whole genome sequencing data","volume":"28","author":"Larson","year":"2012","journal-title":"Bioinformatics"},{"key":"10.1016\/j.ejca.2021.12.003_bib33","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1158\/1055-9965.EPI-13-0761","article-title":"Gene expression profiling in true interval breast cancer reveals overactivation of the mTOR signaling pathway","volume":"23","author":"Rojo","year":"2014","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.ejca.2021.12.003_bib34","doi-asserted-by":"crossref","DOI":"10.3390\/jcm5020013","article-title":"Epithelial-mesenchymal transition and breast cancer","volume":"5","author":"Wu","year":"2016","journal-title":"J Clin Med"},{"key":"10.1016\/j.ejca.2021.12.003_bib35","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1001\/jamaoncol.2016.1061","article-title":"Variation in the incidence and magnitude of tumor-infiltrating lymphocytes in breast cancer subtypes: a systematic review","volume":"2","author":"Stanton","year":"2016","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ejca.2021.12.003_bib36","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.1038\/s41598-020-60255-4","article-title":"The prognostic implications of tumor infiltrating lymphocytes in colorectal cancer: a systematic review and meta-analysis","volume":"10","author":"Idos","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.ejca.2021.12.003_bib37","doi-asserted-by":"crossref","first-page":"1593806","DOI":"10.1080\/2162402X.2019.1593806","article-title":"Prognostic value of tumor-infiltrating lymphocytes in melanoma: a systematic review and meta-analysis","volume":"8","author":"Fu","year":"2019","journal-title":"OncoImmunology"},{"key":"10.1016\/j.ejca.2021.12.003_bib38","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/nrc.2016.14","article-title":"Antitumour actions of interferons: implications for cancer therapy","volume":"16","author":"Parker","year":"2016","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.ejca.2021.12.003_bib39","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/nri3845","article-title":"Type I interferons in anticancer immunity","volume":"15","author":"Zitvogel","year":"2015","journal-title":"Nat Rev Immunol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804921012582?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804921012582?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T16:34:51Z","timestamp":1778517291000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804921012582"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":39,"alternative-id":["S0959804921012582"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2021.12.003","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Interval breast cancer is associated with interferon immune response","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2021.12.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}